Gilead Could Move to Bundle Recent Idenix Patent Disputes, Likely to Hinge on Issues of Prior Art, Invalidity – Attorneys
January 5, 2014
Christine Livoti
BioPharm Insight
Axinn partner Chad Landmon was quoted in Christine Livoti's article, "Gilead Could Move to Bundle Recent Idenix Patent Disputes, Likely to Hinge on Issues of Prior Art, Invalidity – Attorneys," which was published January 9 in BioPharm Insight.
Click here to view the article.